Disease Modifying Activity in Psoriasis and Atopic Dermatitis
A special issue of Journal of Clinical Medicine (ISSN 2077-0383). This special issue belongs to the section "Dermatology".
Deadline for manuscript submissions: closed (20 February 2026) | Viewed by 1138
Special Issue Editors
2. Study Center of the Italian Group for Epidemiologic Research in Dermatology (GISED), Bergamo, Italy
Interests: dermatology; psoriasis; atopic dermatitis; skin; keratinocytes; clinical dermatology; skin cancer; epidemiology; biologic therapy; urticaria
Special Issues, Collections and Topics in MDPI journals
Interests: psoriasis; psoriatic arthritis; atopic dermatitis; metabolic syndrome; vitamin D; alopecia areata; autoimmune bullous diseases; hidradenitis suppurativa; biologic therapy; urticaria
Special Issues, Collections and Topics in MDPI journals
Special Issue Information
Dear Colleagues,
Both psoriasis and atopic dermatitis (AD) have seen significant strides made in the development of therapies with disease-modifying activity. In psoriasis, biologic therapies targeting IL-23, IL-17, and TNF-α have revolutionized the treatment landscape, with strong evidence of long-term disease control and a reduced risk of comorbidities. In AD, therapies targeting the Th2 immune response, such as dupilumab, have shown promising results in modifying the disease course by reducing flares and improving skin health. Emerging treatments, including JAK inhibitors and barrier-repair agents, are also gaining attention for their potential to change the natural history of AD; however, more research is needed to fully understand their long-term impact on disease progression, as well as to identify biomarkers that can predict which patients are most likely to benefit from specific therapies.
This Special Issue will explore the evolving landscape of therapeutic strategies aimed at modifying the course of these diseases. It will highlight the role of biologics, small molecules, and emerging therapies that modulate immune responses, particularly through the inhibition of key cytokines like IL-23, IL-17, and type 2 inflammatory pathways. Key studies and clinical trials will be discussed, focusing on their impact on disease severity, patients’ quality of life, and potential long-term benefits, alongside challenges such as treatment resistance and the need for personalized approaches. The contributions will provide a comprehensive overview of current knowledge on and future directions in disease-modifying treatments for psoriasis and AD.
Dr. Elena Pezzolo
Dr. Paolo Gisondi
Guest Editors
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 250 words) can be sent to the Editorial Office for assessment.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2600 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
Keywords
- atopic dermatitis
- biologics
- psoriasis
- disease-modifying treatment
- small molecules
- type 2 inflammation
Benefits of Publishing in a Special Issue
- Ease of navigation: Grouping papers by topic helps scholars navigate broad scope journals more efficiently.
- Greater discoverability: Special Issues support the reach and impact of scientific research. Articles in Special Issues are more discoverable and cited more frequently.
- Expansion of research network: Special Issues facilitate connections among authors, fostering scientific collaborations.
- External promotion: Articles in Special Issues are often promoted through the journal's social media, increasing their visibility.
- Reprint: MDPI Books provides the opportunity to republish successful Special Issues in book format, both online and in print.
Further information on MDPI's Special Issue policies can be found here.
